Brandi Bratrude
A5009880868- Hematopoietic Stem Cell Transplantation
- Renal Transplantation Outcomes and Treatments
- Immune Cell Function and Interaction
- Inflammatory Bowel Disease
- Immunodeficiency and Autoimmune Disorders
- Single-cell and spatial transcriptomics
- Microscopic Colitis
- Cytomegalovirus and herpesvirus research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Immune cells in cancer
- Chronic Myeloid Leukemia Treatments
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Transplantation: Methods and Outcomes
- Clinical Nutrition and Gastroenterology
- Childhood Cancer Survivors' Quality of Life
- Platelet Disorders and Treatments
- Oral health in cancer treatment
- Viral-associated cancers and disorders
- Pluripotent Stem Cells Research
- IL-33, ST2, and ILC Pathways
- Cancer Genomics and Diagnostics
- Pneumocystis jirovecii pneumonia detection and treatment
- Autoimmune and Inflammatory Disorders Research
Boston Children's Hospital
2020-2024
Dana-Farber Cancer Institute
2020-2024
Harvard University
2020-2023
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2021-2023
Boston Children's Museum
2019
Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need novel therapeutics. ABA2 was phase II trial to rigorously assess safety, efficacy, and immunologic effects adding T-cell costimulation blockade with abatacept calcineurin inhibitor...
Organ infiltration by donor T cells is critical to the development of acute graft-versus-host disease (aGVHD) in recipients after allogeneic hematopoietic stem cell transplant (allo-HCT). However, deconvoluting transcriptional programs newly recruited from those tissue-resident aGVHD target organs remains a challenge. Here, we combined serial intravascular staining technique with single-cell RNA sequencing dissect tightly connected processes which initially infiltrate tissues and then...
Crohn’s disease is an inflammatory bowel (IBD) commonly treated through anti-TNF blockade. However, most patients still relapse and inevitably progress. Comprehensive single-cell RNA-sequencing (scRNA-seq) atlases have largely sampled with established treatment-refractory IBD, limiting our understanding of which cell types, subsets, states at diagnosis anticipate severity response to treatment. Here, combining clinical, flow cytometry, histology, scRNA-seq methods, we profile diagnostic...
We performed a Ph2 trial in adults and children to test abatacept for AGVHD prevention (‘ABA2', Clinicaltrials # NCT01743131), based on our promising preclinical pilot patient data. ABA2 had 2 cohorts: A) HLA-mismatched (‘7/8', n = 43), single-arm study with pre-specified CIBMTR matched analysis (vs CNI+MTX or CNI+MTX+ATG). B) HLA-matched (‘8/8', n = 142), randomized double-blind, comparing CNI+MTX+placebo vs CNI+MTX+ABA (‘ABA'). For each ABA arm, patients received 4 doses of 10mg/kg d...
Crohn’s disease is an inflammatory bowel (IBD) commonly treated through anti-TNF blockade. However, most patients still relapse and inevitably progress. Comprehensive single-cell RNA-sequencing (scRNA-seq) atlases have largely sampled with established treatment-refractory IBD, limiting our understanding of which cell types, subsets, states at diagnosis anticipate severity response to treatment. Here, combining clinical, flow cytometry, histology, scRNA-seq methods, we profile diagnostic...
Abstract Crohn’s disease is an inflammatory bowel (IBD) commonly treated through anti-TNF blockade. However, most patients still relapse and inevitably progress. Comprehensive single-cell RNA-sequencing (scRNA-seq) atlases have largely sampled with established treatment-refractory IBD, limiting our understanding of which cell types, subsets, states at diagnosis anticipate severity response to treatment. Here, combining clinical, flow cytometry, histology, scRNA-seq methods, we profile...